---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Long-term morbidity"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Long-term morbidity. Topics: Cirrhosis: prevalence in US adults with MASLD, NHANES 2017 to 2020; Cirrhosis: progression to clinical decompensation; Hepatic decompensation and hepatocellular cancer by fibrosis stage: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2; Projected decompensated cirrhosis and hepatocellular carcinoma: US NAFLD population, 2015 to 2030 model; 14 further topics. 18 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Cirrhosis: prevalence in US adults with MASLD, NHANES 2017 to 2020

> “We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcohol-associated liver disease (ALD), MetALD, viral hepatitis to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD).”
> “In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.”
> “The prevalence of cirrhosis in the United States is 2.6% while the prevalence of CS-portal hypertension is 0.98%. Individuals with MASLD comprise the majority of US residents with cirrhosis.”

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/)

<a id="topic-2.2.1.7-2"></a>

### Cirrhosis: progression to clinical decompensation

> “Those with cirrhosis require biannual screening for HCC as well as screening for varices and monitoring for signs or symptoms of decompensation.”
> “Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.7-3"></a>

### Hepatic decompensation and hepatocellular cancer by fibrosis stage: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2

> “A total of 1773 adults with NAFLD were followed for a median of 4 years.”
> “The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).”
> “After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).”
> “The study included adults who had liver biopsies that could be evaluated and that revealed NAFLD and who had at least one follow-up visit after 48 weeks.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.7-4"></a>

### Projected decompensated cirrhosis and hepatocellular carcinoma: US NAFLD population, 2015 to 2030 model

> “Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases.”
> “Projected changes in NAFLD‐related cirrhosis, advanced liver disease, and liver‐related mortality were quantified through 2030.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.7-5"></a>

### Hepatocellular carcinoma: incidence in US veterans with NAFLD

> “We compared 296,707 NAFLD patients with 296,707 matched controls. During 2,382,289 person-years [PY] of follow-up, 490 NAFLD patients developed HCC (0.21/1000 PY). HCC incidence was significantly higher among NAFLD patients vs. controls (0.02/1000 PY; hazard ratio, 7.62, 95% confidence interval=5.76–10.09). Among patients with NAFLD, those with cirrhosis had the highest annual incidence of HCC (10.6 /1000 PY).”
> “In medical record reviews, 20% of NAFLD patients with HCC had no evidence of cirrhosis.”
> “We conducted a retrospective cohort study from a total of 130 facilities in the Veterans Health Administration.”

Source: [Kanwal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6279617/)

<a id="topic-2.2.1.7-6"></a>

### Hepatocellular carcinoma without cirrhosis: systematic review and meta-analysis of NAFLD-related HCC

> “Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria.”
> “A higher proportion of patients with NAFLD-related hepatocellular carcinoma did not have cirrhosis (38·5%, 95% CI 27·9–50·2) compared with patients with hepatocellular carcinoma secondary to other causes (14·6%, 8·7–23·4; p<0·0001).”

Source: [Tan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9718369/)

<a id="topic-2.2.1.7-7"></a>

### Hepatocellular carcinoma risk with F3 fibrosis and surveillance recommendations

> “In adults with non-cirrhotic MASLD or MASH in the absence of severe fibrosis (i.e. those with fibrosis stage <F3) assessed by non-invasive markers or liver biopsy, surveillance for early detection of hepatocellular carcinoma is currently not recommended (LoE 3, weak recommendation, consensus).”
> “In adults with non-cirrhotic MASLD or MASH in the presence of severe fibrosis (F3) assessed by non-invasive markers or liver biopsy, surveillance may be considered based on an individual risk assessment (LoE 4, weak recommendation, strong consensus).”
> “Individuals with F3 fibrosis have an intermediate risk of developing HCC that is lower than that of individuals with cirrhosis, but not negligible.”
> “In the national Veterans Affairs study, a FIB-4 >2.67, suggestive of advanced fibrosis (F3/F4), was associated with an increased risk of HCC (0.39/1,000 vs. 0.04/1,000 PY in individuals with persistently low FIB-4) in the absence of cirrhosis.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.7-8"></a>

### Liver transplantation: NASH/MASH share of US and European transplant recipients, 2000 to 2022

> “Data from 2 large LT registries: the US Scientific Registry of Transplant Recipients (SRTR) and the European Liver Transplant Registry (ELTR), years 2000-2022, were compared.”
> “NASH/MASH also increased: SRTR 9%-28%, ELTR 5%-12%. From SRTR, NASH/MASH was the common etiology by 2022;”
> “ALD and NASH/MASH are now leading indications for liver transplantation in 2 large global regions.”

Source: [Younossi et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/40674288/)

<a id="topic-2.2.1.7-9"></a>

### Liver transplantation: MASH share of the US waitlist for steatotic liver disease, 2010 to 2023

> “Steatotic liver disease (SLD) is the leading indication for liver transplantation (LT) among U.S. adults.”
> “We identified 65,675 adults on the LT waitlist secondary to SLD (median age 57 years old [IQR 50–64], 65.1% men, 74.9% NHW, 3.2% AA, 17.9% Hispanic, 2.5% API, 1.1% AI/AN, and 0.5% multiracial) from 2010 to 2023 (Table 1). Overall, 44.5% had MASH (vs 55.5% ALD) while 17.2% had HCC (vs 82.8% non-HCC).”

Source: [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11869966/)

<a id="topic-2.2.1.7-10"></a>

### Cardiovascular disease: risk of fatal and non-fatal events by severity of NAFLD, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.”
> “NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61;”
> “This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72;”
> “CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage.”

Source: [Mantovani et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34555346/)

<a id="topic-2.2.1.7-11"></a>

### Cardiovascular disease: principal cause of death, American Heart Association scientific statement

> “In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD.”

Source: [Duell et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35418240/)

<a id="topic-2.2.1.7-12"></a>

### Cardiovascular disease: atherosclerosis, heart failure, and arrhythmia

> “The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.”
> “A strong association exists between NAFLD and atherosclerotic heart disease, heart failure, and arrhythmias, particularly atrial fibrillation.”
> “Furthermore, in a large prospectively studied observational cohort, the incidence of cardiac events was the same across all fibrosis stages; however, the number of cardiac events was relatively low.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40),”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.7-13"></a>

### Chronic kidney disease: risk of incident CKD, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.”
> “NAFLD was associated with a moderately increased risk of incident CKD (n=10 studies; random-effects HR 1.43, 95% CI 1.33 to 1.54;”
> “All risks were independent of age, sex, obesity, hypertension, diabetes and other conventional CKD risk factors.”

Source: [Mantovani et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33303564/)

<a id="topic-2.2.1.7-14"></a>

### Chronic kidney disease: higher prevalence with advanced fibrosis

> “A meta-analysis of 20 cross-sectional studies (n = 28,000 individuals) found that NAFLD was associated with a 2-fold increased prevalence of CKD.”
> “Recently published data from the NASH CRN demonstrate a higher prevalence of CKD in patients with advanced fibrosis compared with lower fibrosis stages.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Emerging evidence suggests that MASLD increases the risk of CKD in people with type 2 diabetes, particularly when liver fibrosis is present”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.7-15"></a>

### New-onset nonhepatic outcomes: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2

> “New-onset hypertension (7.8 events per 100 person-years) was the most common new nonhepatic outcome, followed by type 2 diabetes (4.8 events per 100 person-years), chronic kidney disease (2.5 events per 100 person-years), cardiac events (0.8 events per 100 person-years), nonhepatic cancer (0.8 events per 100 person-years), and cerebrovascular events (0.4 events per 100 person-years).”
> “As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.7-16"></a>

### Type 2 diabetes: incident diabetes in NAFLD

> “The presence of NAFLD is associated with a 2- to 5-fold risk of incident diabetes,”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.7-17"></a>

### Extrahepatic cancer: risk of incident extrahepatic cancers, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.”
> “NAFLD was significantly associated with a nearly 1.5-fold to twofold increased risk of developing GI cancers (oesophagus, stomach, pancreas or colorectal cancers). Furthermore, NAFLD was associated with an approximately 1.2-fold to 1.5-fold increased risk of developing lung, breast, gynaecological or urinary system cancers.”

Source: [Mantovani et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/33685968/)

<a id="topic-2.2.1.7-18"></a>

### Extrahepatic cancer: leading contributor to excess mortality in biopsy-confirmed NAFLD, Sweden

> “This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).”
> “The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).”

Source: [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/)

> “In the general population, MASLD is not associated with increased overall cancer-related mortality,”
> “but it is associated with higher risk of HCC and certain extrahepatic cancers, mostly thyroid and gastrointestinal.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
